Innovative Breast Cancer Education Programs for African-Americans

Publication
Article
OncologyONCOLOGY Vol 13 No 3
Volume 13
Issue 3

African-Americans are leading the fight against breast cancer in communities across the country. The Witness Project, the East-West Breast Express, and the Navigator Program are just a few examples of innovative programs funded by the Susan G. Komen Breast Cancer Foundation and their local affiliates that are improving the future for many African-American women.

African-Americans are leading the fight against breast cancer in communities across the country. The Witness Project, the East-West Breast Express, and the Navigator Program are just a few examples of innovative programs funded by the Susan G. Komen Breast Cancer Foundation and their local affiliates that are improving the future for many African-American women.

The Witness Project

“In church, people witness to save souls. At the Witness Project, they witness to save lives,” said Mattye J. Willis, deputy director of the Witness Project, a national program that enlists African-American breast cancer survivors to share their stories with other African-American women in their community to educate them about the disease.

The Witness Project reaches women through their local churches. “This is where women are comfortable talking about themselves. ‘I am your sister, I am concerned about your health,’ ” said Ms. Willis. “Witnesses also reach out to men through the church. Many women will move faster if the men in their lives are supportive.”

Early detection is the witnesses’ main message. “We want to challenge deeply held cultural beliefs that a woman should not touch her body or talk about her health,” said Ms. Willis. From 6 to 8 weeks after the initial meeting, witnesses (volunteers) follow up with each woman and help set up mammography appointments. They also help with any barriers to screening, such as arranging for transportation and child care.

Established in 1991 by the Arkansas Cancer Research Center in Little Rock, the Witness Project was initially funded by the Komen Foundation. In October 1997, the Centers for Disease Control provided a $1 million, 4-year grant for replicating the program nationwide.

The East-West Breast Express

“Go to the people.” That is the simple concept behind a program developed by Selma Morris, MEd, director of the Comprehensive Breast Center at Emory University School of Medicine and a member of the African American Woman’s Initiative (AAWI). The East-West Breast Express provides breast health education and screenings to African American women at bus stops, train stations, and other public transportation sites.

The concept for the Breast Express originated in 1994, when a fellow bus passenger commented on Ms. Morris’ pink ribbon. “When I explained that the ribbon symbolized breast health, she did not understand what I was talking about,” said Ms. Morris. Over the next few days, several other people inquired about the pin and the idea for the program was born.

Community health advocates and volunteers visit train and bus stations to provide “one-on-one” education in Atlanta (in partnership with MARTA [Metropolitan Atlanta Rapid Transit Authority]) and Oakland, California(in partnership with BART [Bay Area Rapid Transit]), where the program is coordinated by Bonnie Wheatley, project director of the Breast Cancer Early Detection Program in Oakland and an AAWI member.

Individuals take a short survey to determine the level of their breast health knowledge and receive a bag with educational information and free gifts (ie, Tropicana coupons, ethnic cookbooks). Mobile vans are also on site to provide free screenings.

The program, funded by the Komen Foundation, was tested in Atlanta and Oakland from April to July 1998. Each program reached over 2,000 women and men. Of those eligible, 50% had mammograms. Now, Ms. Morris is working to expand the program to a national level.

Harlem Hospital Patient Navigator Program

Navigating the health care system can be an insurmountable barrier for many women when it comes to taking care of themselves, especially when they no or inadequate insurance. Helping women navigate through the system, from screening to diagnosis to treatment and beyond, is the idea behind the Patient Navigator Program at Harlem Hospital in New York.

“The Patient Navigator is designed to remove the cultural, economic, social and medical barriers to quality health care,” said Harold P. Freeman, md, who developed the program in 1990 and is director of the Department of Surgery at Harlem Hospital Center and former president of the American Cancer Society.

The idea for the program is based on research showing that poor people, including the underinsured and uninsured, endure greater pain and suffering from cancer and face greater obstacles in obtaining and using health insurance. In addition, the poor often do not seek needed care if they cannot pay for it, must make extraordinary personal sacrifices to obtain and pay for health care, and have a fatalistic attitude that prevents them from gaining quality health care.

The Patient Navigator Program is the nucleus of the Cancer Control Center, which was established in late 1989 with the mission of reducing the disproportionately high incidence of and mortality from cancer in the Harlem community. The “navigator” is a proactive patient advocate—distinct from the hospital social worker—who focuses on the specific needs of cancer patients and guides those patients through the system.

“The role of the patient navigator is to help patients understand their options. Let us worry about the obstacles,” said Dr. Freeman. For example, the patient navigator can establish emergency Medicaid coverage for patients, ensuring that they do not have to wait for or miss diagnostic or treatment procedures.

Patients enter the program through free screening clinics at the hospital. The clinics are promoted by outreach workers, who spread the word about the need for early detection at beauty salons, senior centers, and other community hubs. Patient navigators then identify patients who need “navigation” due to abnormal breast examinations. Through a series of visits and follow-up phone calls, patient navigators make sure that patients’ fears about diagnosis and treatment are allayed and that they do not “fall through the cracks.”

Impact of the Program

In 1997, of the more than 2,000 people who were screened through the Patient Navigator Program, nearly half were uninsured. As proof of the program’s impact on the community, the diagnosis of women with stage I breast cancer has increased from 1 out of 20 women in 1989, to 4 out of 10 women. The average length of time between initial breast examination and biopsy for the uninsured decreased to 10 days. In contrast, at most public hospitals across the country, the length of time can be as long as 60 to 90 days, according to Dr. Freeman.

The program is funded in part through support from the Komen Foundation New York Affiliate, New York Race for the Cure.

Articles in this issue

WHO Declares Lymphatic Mapping to Be the Standard of Care for Melanoma
Rituximab: Phase II Retreatment Study in Patients With Low-Grade or Follicular Non-Hodgkin’s Lymphoma
Response Criteria for NHL: Importance of “Normal” Lymph Node Size and Correlations With Response
Chemotherapy Plus Radiation Improves Survival in Patients With Cervical Cancer
A Randomized Trial of Fludarabine, Mitoxantrone (FM) Versus Doxorubicin, Cyclophosphamide, Vindesine, Prednisone (CHEP) as First Line Treatment in Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma: A Multicenter Study by GOELAMS Group
Navelbine Increased Elderly Lung Cancer Patients’ Survival
Fludarabine Versus Conventional CVP Chemotherapy in Newly C Diagnosed Patients With Stages III and IV Low-Grade Malignant Non-Hodgkin’s Lymphoma: Preliminary Results From a Prospective, Randomized Phase III Clinical Trial in 381 Patients
Multicenter, Phase III Study of Iodine-131 Tositumomab (Anti-B1 Antibody) for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade Non-Hodgkin’s Lymphoma
T-Cell–Depleted Allogeneic Bone Marrow Transplant From HLA-Matched Sibling Donors for Non-Hodgkin’s Lymphoma
Consensus Statement on Prevention and Early Diagnosis of Lung Cancer
In Vivo Purging and Adjuvant Immunotherapy With Rituximab During PBSC Transplant For NHL
Fludarabine and Cyclophosphamide: A Highly Active and Well-Tolerated Regimen for Patients With Previously Untreated Indolent Lymphomas
Campath-1H Monoclonal Antibody in Therapy for Advanced Low-Grade Non-Hodgkin’s Lymphomas: A Phase II Study
AIDS Drugs Effective Against Most Common HIV Strain
Rituximab Therapy in Previously Treated Waldenström’s Macroglobulinemia: Preliminary Evidence of Activity
Related Videos
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Related Content